Frankfurt Oder

Researchers are collecting data in a registry study focused on adults with newly diagnosed or relapsed acute myeloid leukemia (AML). The study aims to gather detailed epidemiological information such as age, prognostic factors, and subgroup distributions. It also compares AML incidence and age distribution with population-based tumor registry data. Important clinical outcomes like relapse-free survival, time to relapse, cumulative incidence of relapse, and overall survival are being evaluated over a 10-year period. This study does not involve experimental treatments but instead documents current treatment strategies used in AML patients. Data collection occurs at 60 investigator sites across Germany, providing a broad overview of patient characteristics and management. There is no upper age limit, and all adult patients diagnosed according to WHO criteria, including acute promyelocytic leukemia, are eligible. Participants will be followed for up to 10 years, during which epidemiological parameters and survival outcomes will be monitored. Researchers will record relapse events, time until relapse, and survival status to understand long-term outcomes. This extensive follow-up intends to support improved knowledge about AML patient prognoses and treatment impacts over time.

Researchers are conducting the German Dementia Registry (DEMREG), a large national study in Germany that collects ongoing data from patients diagnosed with cognitive issues such as Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI), and early dementia from various causes. This registry aims to gather real-world, long-term information aligned with clinical guidelines to better understand the natural progression of dementia and differentiate between types like Alzheimer's and other dementias. The study also seeks to track biomarker changes and treatment patterns in routine healthcare settings, which may improve early diagnosis and treatment approaches for dementia. This is an observational registry study where no treatments are provided as part of the research. Instead, the study documents patients' usual care and medications while collecting additional data through questionnaires and tests related to early dementia. Data collection occurs during patient visits using an online platform, integrating clinical routine procedures and biomarker measurements such as cerebrospinal fluid and imaging results. The registry follows patients prospectively over time to monitor disease progression and biomarker changes. Participants and their family members provide informed consent and contribute data at baseline visits, with follow-up visits occurring annually for as long as possible. The registry gathers comprehensive clinical, biomarker, and questionnaire data to analyze dementia's natural history and healthcare practices in Germany. This ongoing data collection supports better understanding and potential improvements in dementia diagnosis and care. There is no maximum age limit for participation, and the registry includes both patients and involved family members.

Researchers are studying men with metastatic castration-resistant prostate cancer (mCRPC) who are starting treatment with lutetium (177Lu) vipivotide tetraxetan. This observational study aims to describe routine clinical practice and how this treatment affects patients' health-related quality of life (HRQoL) from before treatment through to post-progression. The study collects detailed data on patient well-being, symptom changes, and disease progression over time. Patients will receive lutetium (177Lu) vipivotide tetraxetan as determined by their doctors according to local guidelines. Treatment cycles last about 6 weeks, and patients may receive up to 6 cycles. Data is collected at key points including before treatment starts, on the first day of treatment, during each treatment cycle, at the end of treatment, and during follow-up visits. This approach helps capture the full patient experience with this therapy in real-world settings. During the study, participants complete various questionnaires assessing quality of life, cancer symptoms, and pain levels. Researchers also monitor clinical progression, radiographic changes, prostate-specific antigen (PSA) levels, and survival outcomes for up to one year after treatment ends. This comprehensive data collection aims to provide insights into treatment impact, symptom control, and overall patient health over time.

Researchers are studying the use of venetoclax in people with chronic lymphocytic leukemia (CLL) to understand how effective it is and to assess the costs and patient-reported outcomes when used in real-life medical settings. The study looks at venetoclax given alone or combined with rituximab, obinutuzumab, ibrutinib, or acalabrutinib, based on doctors' decisions and local treatment guidelines. Participants receive venetoclax therapy as prescribed by their physician, which may include the drug alone or along with one of the mentioned combination treatments. The study follows patients in Austria, Germany, and Switzerland, observing how the treatments are used in everyday practice without altering the prescribed therapy. During the study, participants are monitored for up to 12 months to measure the percentage who achieve the best overall response rate (ORR) to treatment. Researchers also collect data on health economics and patient experiences to better understand the impact of these therapies in routine care.